Fri, 17th Jun 2016 06:51
LONDON, June 17 (Reuters) - British drug developer Scancell said on Friday it was suspending dosing in a cancerclinical trial because of quality problems with itsimmunotherapy treatment SCIB1.
The company said tests showed the product, which is beingassessed for melanoma, was "no longer within the originalspecification".
Scancell is planning to make a fresh batch of SCIB1. (Reporting by Ben Hirschler; Editing by Alexander Smith)
(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic....
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported...
(Alliance News) - Scancell Holdings PLC on Tuesday reported a narrowed loss as it gained on the revaluation of derivative liability.
Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease said - Receives approval fro...
(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of share...
Scancell Holdings (SCLP)